Proteins are integral to most newly approved drugs, and Generate Biomedicines thinks it can generate a whole host of new therapeutics based on the “building blocks of life,” with multiple candidates…
Researchers at the University of Heidelberg treated rat models of alcohol addiction with the active ingredient in magic mushrooms, psilocybin, and found that the psychedelic restored expression of a…
If approved by the FDA, the MoveAgain system will join an exclusive club—so exclusive, in fact, that only one other brain-computer interface has so far been cleared for commercialization.
When Johnson & Johnson nabbed Penny Heaton, M.D., from the Bill & Melinda Gates Medical Research Institute to be the global therapeutic area head for vaccines at Janssen, they threw her right into the…
With more self-contained models potentially on their way to patients, the FDA is taking steps to remind healthcare providers of certain risks posed by leadless pacemakers, including the possibility of…
Cassava Sciences is forging ahead with a second phase 3 trial of its troubled Alzheimer’s drug just three days after revealing a federal investigation into the company.
Situating the Massachusetts-based CRO under the Labcorp umbrella will give the testing giant a stronger foothold specifically in the Boston area, a hotbed for biotech and pharma development.
Lars Fruergaard Jørgensen has landed the major takeover he has targeted since taking over as CEO of Novo Nordisk. Having missed out on Ablynx to Sanofi in 2018, Novo Nordisk has agreed to a $3.3…
Piece by piece, AstraZeneca is building the case for its COVID-19-preventing antibodies. The latest analysis moves AstraZeneca a step closer to its goal of achieving 12 months of protection with one…
Nonalcoholic fatty liver disease has claimed another victim, this time Bristol Myers Squibb is washing its hand of the midstage asset pegbelfermin. The New York Big Pharma has discontinued development…
